Roche Presents New Elecsys pTau217 Blood Test Performance Data at AAIC 2026 Across Primary and Secondary Care Settings: The In Vitro Diagnostic Test Developed in Collaboration With Eli Lilly Received CE Mark Certification in May 2026 as a Rule-In and Rule-Out Assay for Amyloid Pathology With the Same High and Low Cutoffs Usable Across Care Settings, Presented at AAIC as Part of Roche's Integrated Pharmaceutical and Diagnostics Alzheimer's Portfolio Program
Roche (SIX: ROG) presented new Elecsys plasma phosphorylated-tau 217 (pTau217) blood test performance data at AAIC 2026 in London (July 12-15, 2026) covering both primary care and secondary care settings. The Elecsys pTau217 in vitro diagnostic assay, developed in collaboration with Eli Lilly, received CE Mark certification on May 12, 2026 as an amyloid-pathology rule-in and rule-out test for adults presenting with symptoms of cognitive decline. The same high and low cutoffs of the blood test can be used across primary care (family physicians, general internists) and secondary care (memory clinics, neurology specialty practice) to rule in or rule out amyloid pathology, which simplifies the diagnostic pathway substantially compared with amyloid PET imaging or lumbar puncture. The AAIC 2026 presentations evaluated Elecsys pTau217 performance across both care settings and add real-world diagnostic evidence to the tau-blood-test infrastructure that Eli Lilly's Samantha Burnham anchored earlier in the week with the rule-in-versus-amyloid-PET data set. Roche's AAIC 2026 program spanned undiagnosed Alzheimer's pathology in cardiovascular patients, ApoE4-dependent CETP-inhibitor dose response, and Alzheimer's diagnostic-and-therapeutic integration.